Back to Sites

Soweto IMPAACT CRS

Site Number

8052

Address

Soweto IMPAACT CRS
Old Potch Road
PHRU, Chris Hani Baragwanath Hospital
P.O.Box 114, Diepkloof
12th Floor
Johannesburg, Gauteng 2091
South Africa

IMPAACT Members at this Site

Janice Buckley Co-Investigator

Deirdre Josipovic CRS Coordinator

Avy Violari CRS Leader

Gugulethu Mkhize CRS Staff

Fatima Mayat CTU Coordinator

Glenda Gray CTU Principal Investigator

Lerato Mohapi CTU Principal Investigator

Ravindre Panchia CTU Principal Investigator

Gail Tauscher DAIDS PO

Niven Naicker Data Manager

Marianne Kohler Investigator

Shabir Madhi Investigator

Sisinyana Mathiba Investigator

Peter Adrian Local Laboratory

Wendy Stevens Local Laboratory

Rita-Mari Badenhorst Pharmacist

Carita Marx Pharmacist

James McIntyre Principal Investigator

Precious Modiba Regulatory Coordinator

Tebogo Magopane Staff

Ntatule Ndiweni Study Coordinator

Wilma Pelser Study Coordinator

Prasha Sriram Study Coordinator

Studies at this Site

P1101: Phase I/II Dose-Finding, Safety, Tolerance and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-infected and TB Co-infected Infants and Children

DAIDS Number

11831

Research Area

Treatment

Study Status

Concluded

P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls

DAIDS Number

11878

Research Area

Brain and Mental Health

Study Status

Participants Off Study and Primary Analysis Completed

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

DAIDS Number

11882

Research Area

Therapeutics

Study Status

Closed to Follow Up

IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection

DAIDS Number

20734

Research Area

Treatment

Study Status

Concluded

IMPAACT 2010: VESTED

DAIDS Number

30129

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2014: Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

DAIDS Number

34150

Research Area

Treatment

Study Status

Concluded

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Brain and Mental Health

Study Status

Closed to Accrual

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

38504

Research Area

Therapeutics

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

38637

Research Area

Therapeutics

Study Status

Enrolling

IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV

DAIDS Number

38693

Research Area

Cure and Immunotherapy

Study Status

Enrolling